Understanding Ketamine Safety: Risks, Side Effects, and Best Practices

Ketamine is generally safe when given by trained clinicians in a monitored setting, but understanding ketamine safety means separating two different bodies of evidence: five decades of anesthesia and emergency medicine use, and the newer practice of repeated, low-dose psychiatric dosing that has only been studied closely since the early 2000s.

Ketamine received FDA approval as an anesthetic in 1970 and has been used continuously since in anesthesia, emergency medicine, pediatrics, pain management, and psychiatry. The World Health Organization lists ketamine on its Model List of Essential Medicines, a designation reserved for medicines with a well-established safety and efficacy profile for their approved uses. The psychiatric application, repeated sub-anesthetic infusions or doses over months or years, is a different use case than the single-dose anesthetic and emergency applications that built ketamine's original safety record. This guide covers the acute side effects, contraindications, drug interactions, long-term risks, and monitoring protocols that define ketamine's safety profile in a clinical psychiatric setting.

Dissociative Effects

Dissociation is the most characteristic acute effect of ketamine at sub-anesthetic doses. It is not a side effect in the traditional sense, it is a core pharmacological property of the drug tied to NMDA receptor antagonism. Patients may notice a sense of floating or detachment from the body, altered perception of time, dreamlike visual experiences, heightened sensitivity to sound, and distance from usual thought patterns; some describe the experience as spiritual or mystical. See our guide to understanding dissociation for more on why this state occurs and how it can be clinically useful.

Intensity is dose-dependent and varies by individual. At the standard IV dose of 0.5 mg/kg over 40 minutes, most patients experience mild to moderate dissociation that peaks during infusion and resolves within 60-90 minutes. Preparation, an appropriate setting, and supportive clinical staff, the elements covered in our set and setting guide, meaningfully improve the experience for patients who find dissociation uncomfortable.

Cardiovascular Effects

Ketamine is sympathomimetic: it temporarily increases sympathetic nervous system activity. Systolic blood pressure typically rises 15-25 mmHg during treatment, heart rate may increase 10-20 beats per minute, and cardiac output rises, which is one reason ketamine is favored in emergency settings for hemodynamically unstable patients. These changes are clinically insignificant in healthy individuals and typically return to baseline within 30-60 minutes, but they require careful consideration in patients with cardiovascular risk factors. Standard monitoring includes blood pressure checks before, during, and after treatment, continuous heart rate tracking, and pulse oximetry, with predetermined thresholds for pausing treatment if blood pressure exceeds safe limits.

Nausea, Dizziness, and Coordination

Nausea affects roughly 15-30% of patients receiving sub-anesthetic ketamine, and vomiting occurs in about 5-10%. Risk factors include higher doses, faster infusion rates, female sex, a history of motion sickness, and oral or sublingual administration. Pre-treatment antiemetics, ginger, slower infusion rates, and a 4-6 hour fast before treatment, with clear liquids typically permitted, help manage this risk. Dizziness and impaired coordination are also common during and shortly after treatment, which is why patients are instructed not to drive or operate machinery for at least 12-24 hours afterward.

Visual Changes, Headache, and Psychological Effects

Visual disturbances, including blurred or double vision and mild distortions, are common, dose-related, and typically resolve within 1-2 hours without indicating any underlying problem. About 15-20% of patients report headache after treatment, usually mild and responsive to standard over-the-counter analgesics. A smaller share of patients experience anxiety during the dissociative state, particularly if unprepared, emotional release such as crying, confusion during acute effects, or vivid dreams afterward. These effects are generally self-limiting, and proper preparation and supportive clinical staff reduce both their frequency and intensity.

Absolute Contraindications

• Uncontrolled hypertension. Ketamine raises blood pressure, so it should not be used until blood pressure is adequately managed.
• Active psychotic disorders. Patients with active schizophrenia, schizoaffective disorder, or other psychotic disorders should not receive ketamine, since its effects on glutamate and its psychotomimetic properties at higher doses could theoretically worsen psychotic symptoms. A history of psychosis does not automatically rule out treatment if the patient is currently stable and under psychiatric care, but this requires careful clinical judgment.
• Known hypersensitivity to ketamine.
• Pregnancy. Ketamine is not recommended during pregnancy due to insufficient safety data and potential concerns about fetal development; animal studies at high doses have raised neurodevelopmental concerns, though relevance to human sub-anesthetic use is unclear.
• Intracranial hypertension. Historically considered a contraindication in raised intracranial pressure; more recent evidence suggests the concern may be overstated, but caution remains appropriate.

Relative Contraindications and Cautions

• Cardiovascular disease such as unstable angina, recent myocardial infarction, heart failure, aortic aneurysm, or arrhythmias warrants cardiovascular evaluation and may require cardiology clearance, lower doses, or slower infusion rates.
• Liver disease. Ketamine is metabolized primarily by the liver, so significant hepatic impairment can slow clearance and prolong effects, calling for dose adjustments and monitoring.
• History of substance use disorders. Ketamine has abuse potential. Active or recent substance use disorders, particularly involving ketamine, PCP, or other dissociatives, call for a careful risk-benefit assessment and closer monitoring rather than an automatic exclusion.
• Bladder conditions such as interstitial cystitis or overactive bladder require careful monitoring, since ketamine can affect bladder function.
• Thyroid disorders. Uncontrolled hyperthyroidism can amplify ketamine's cardiovascular effects and should be managed before treatment.
• Glaucoma. Ketamine may temporarily raise intraocular pressure.

Medications That May Reduce Ketamine's Effects

Benzodiazepines such as lorazepam, diazepam, clonazepam, and alprazolam may reduce ketamine's antidepressant efficacy by dampening the glutamate surge and AMPA receptor activation central to its mechanism, based on preclinical and some clinical evidence. Some clinicians recommend tapering benzodiazepines before starting ketamine therapy, weighed against the risks of withdrawal. Lamotrigine, a mood stabilizer that also modulates glutamate release, has shown mixed evidence: some studies suggest it reduces ketamine's dissociative effects without affecting antidepressant efficacy, while others suggest possible attenuation of the antidepressant effect itself.

Medications That May Amplify Effects

CNS depressants, including opioids, alcohol, and sedative-hypnotics, can potentiate ketamine's sedative and respiratory depressant effects, so patients should disclose all CNS-active substances to their provider. MAO inhibitors may theoretically interact with ketamine's sympathomimetic effects, though clinical data are limited. Combining ketamine with stimulants may increase cardiovascular strain and can call for additional blood pressure monitoring. Patients on serotonergic medications should also discuss the risk of serotonin syndrome with their prescriber when multiple serotonergic agents are combined.

Medications Generally Safe to Combine

Ketamine can generally be used alongside most common psychiatric medications, including SSRIs, SNRIs, bupropion, mirtazapine, lithium, and most atypical antipsychotics. Patients should still provide a complete medication list to their prescribing clinician and coordinate any medication changes with the ketamine provider.

Bladder Health

The best-known long-term concern with ketamine is urological damage, particularly ketamine-induced cystitis, which is well documented in chronic recreational users and can involve reduced bladder capacity, urinary frequency and urgency, pelvic pain, and in severe cases ulceration and fibrosis of the bladder wall. The distinction is dose and frequency: recreational bladder damage is typically linked to daily or near-daily use of 1-5 grams per day or more over months to years, while therapeutic use involves much lower doses, typically around 0.5 mg/kg per session, given weekly to monthly, with cumulative exposure that is orders of magnitude lower. Current evidence does not show that ketamine therapy at standard clinical doses and frequencies causes significant bladder pathology, and multiple studies of patients receiving repeated therapeutic ketamine have not found clinically significant urological effects. Clinics still monitor for urinary symptoms as standard practice, and any emerging symptoms should prompt evaluation.

Cognitive Function

During and shortly after treatment, ketamine impairs attention, working memory, and executive function; these effects are dose-dependent and fully reversible, typically resolving within 2-4 hours. Long-term heavy recreational use has been linked to deficits in episodic memory, semantic memory, and executive function in some studies, deficits that appear dose-dependent and may be partially reversible with cessation. By contrast, studies of patients receiving repeated therapeutic ketamine at standard clinical doses and frequencies have generally not found clinically significant long-term cognitive impairment, and some have reported improvement likely tied to the resolution of depression, which itself impairs cognition.

Dependence and Addiction Potential

Ketamine is a Schedule III controlled substance in the United States, indicating moderate potential for dependence. According to the National Institute on Drug Abuse, ketamine's dissociative and reinforcing effects give it recognized potential for misuse outside a monitored medical setting. Physical dependence with a defined withdrawal syndrome can develop with chronic daily use at high doses, but this has not been reported at therapeutic doses and frequencies, and reports of patients developing dependence on their therapeutic ketamine are rare in the published literature. Patients with a personal or family history of substance use disorders, particularly involving dissociatives, stimulants, or opioids, warrant additional screening. Common safeguards include prescribing controlled amounts rather than large supplies, regular clinical assessments for escalating use, structured protocols with defined endpoints, and, in many practices, a signed treatment agreement.

Hepatic Effects

Ketamine is metabolized by the liver, primarily through the cytochrome P450 enzymes CYP2B6 and CYP3A4. Clinically significant hepatotoxicity has not been reported at standard therapeutic doses, but patients receiving long-term, frequent ketamine should have periodic liver function monitoring, and those with pre-existing liver disease may require dose adjustments. Some case reports describe elevated liver enzymes in patients receiving very frequent or high-dose ketamine, typically normalizing once treatment is adjusted.

Older Adults

Older adults may need dose adjustments because of age-related changes in drug metabolism, body composition, and cardiovascular function. Lower starting doses, gradual titration, more intensive cardiovascular monitoring, and attention to fall risk during recovery are often appropriate.

Adolescents

Ketamine use in adolescents for psychiatric conditions is an area of active investigation. The developing brain may respond differently to NMDA receptor modulation, and long-term effects on neurodevelopment are not fully established, so treatment in this population should be undertaken only by experienced clinicians with careful monitoring.

Patients With Trauma Histories

Patients with significant trauma histories may be more sensitive to ketamine's dissociative effects. Dissociation can be therapeutically productive in a supportive setting, but it can also be distressing for some trauma survivors. Careful preparation, lower starting doses, and the availability of a trained therapist during treatment, an approach covered in our guide to ketamine-assisted psychotherapy, are important considerations.

Standard monitoring during each session includes blood pressure at baseline, during treatment, and post-treatment, along with heart rate and rhythm, pulse oximetry, level-of-consciousness checks, and documentation of any adverse events. After each session, patients should remain in the clinical setting until acute effects resolve and vital signs stabilize, be assessed for steady gait before discharge, have a responsible adult available for transportation, and know how to reach the clinical team if concerning symptoms arise afterward.

Patients on an ongoing course of therapy should have regular follow-up that tracks treatment response with standardized measures, watches for signs of tolerance, screens for urinary symptoms, includes periodic liver function testing based on treatment intensity, and coordinates with other treating clinicians. Our guide to finding a ketamine provider covers questions to ask about a clinic's monitoring protocols before starting treatment.

The growing availability of at-home ketamine therapy, primarily oral and sublingual formulations prescribed through telehealth providers, raises safety considerations that differ from in-clinic IV or IM treatment. Our guide to at-home ketamine safety covers this in more depth, but the core safeguards are consistent across reputable telehealth programs.

FDA Oversight

Esketamine nasal spray, sold as Spravato and the FDA-approved esketamine formulation, can only be administered in certified healthcare settings under a Risk Evaluation and Mitigation Strategy, or REMS, that requires mandatory two-hour monitoring after each dose. The FDA has also issued guidance addressing compounding pharmacy practices related to ketamine, and its MedWatch program collects reports of adverse events associated with ketamine use.

State Regulations

Many states have implemented or are developing regulations specific to ketamine therapy clinics, covering provider qualifications, required monitoring protocols, documentation standards, prescribing limitations for at-home use, and telehealth prescribing requirements. Rules vary by state, so patients evaluating a provider should confirm the clinic meets local requirements; our overview of ketamine's legal status covers how this varies.